Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry

Introduction

Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic competition. However, the speed and severity of brand erosion is by no means equal across countries, prescribing setting, therapy area and formulation type; factors which are of key importance when managing and forecasting branded drug sales.

Features and benefits

* Analyzes brand erosion (in terms of volume and value) in the US, Japan, France, Germany, Italy, Spain, UK, Australia China and Russia
* Assesses brand erosion across the two major prescribing settings (retail and hospital)
* Examines brand erosion across the various different therapy areas
* Analyzes brand erosion according to drug formulation (oral, oral long lasting, parenteral and other formulation types)

Highlights

Brands tended not to experience generic erosion in China following patent expiry since they often face generic competition from the outset, and instead continue to grow both in terms of volume and value.
Brand erosion was greater in terms of speed and severity in the hospital setting most likely reflecting the greater brand loyalty among patients in the retail setting.
In terms of erosion by therapy areas, sales and volume erosion was the greatest among infectious disease, oncology, and cardiovascular small molecule brands.

Your key questions answered

* Evaluate the evolving prescription pharmaceutical landscape and how this is being impacted by generics
* Quantify sales and volume erosion across 10 major pharmaceutical markets according to prescribing setting, therapy areas, and drug formulation
* Assess drivers and resistors for the uptake of generic drugs in each market
[Studien Infos ausblenden]

Executive Summary
Introduction
Strategic Scoping and Focus
Key Findings
Brand erosion by country
Brand erosion by prescribing setting (retail versus hospital)
Brand erosion by therapy area
Brand erosion by formulation
Overview of drugs analyzed
Related Reports
Upcoming related reports
2. BRAND EROSION ACROSS THE WORLD’S MAJOR MARKETS
Overview of brand erosion across the world’s major markets
3. GENERICS MARKET DYNAMICS
Comparison of generic penetration across major pharmaceutical markets
Generics volume uptake
Generics value uptake
Generics market size
4. GENERICS DRIVERS AND RESISTORS
Overview of Generics Drivers and Resistors
US – Generics drivers and resistors
Japan – Generics drivers and resistors
France – Generics drivers and resistors
Germany – Generics drivers and resistors
Italy – Generics drivers and resistors
Spain – Generics drivers and resistors
UK – Generics drivers and resistors
China – Generics drivers and resistors
Brazil – Generics drivers and resistors
India – Generics drivers and resistors
Russia – Generics drivers and resistors
Australia – Generics drivers and resistors
5. BRAND EROSION IN THE RETAIL AND HOSPITAL SETTING
Overview of brand erosion in the retail and hospital setting
Retail and hospital erosion by country
6. BRAND EROSION BY THERAPY AREA
Overview of brand erosion by therapy area
Brand erosion by therapy area – Infectious diseases
Brand erosion by therapy area – Cardiovascular
Brand erosion by therapy area – Oncology
Brand erosion by therapy area – Central Nervous System
Brand erosion by therapy area – Respiratory
Brand erosion by therapy area – Metabolic disorders
Brand erosion by therapy area – Immunology and inflammation
Brand erosion by therapy area – Other
7. BRAND EROSION BY DRUG FORMULATION
Overview of brand erosion by drug formulation
Brand erosion by drug formulation – Oral
Brand erosion by drug formulation – Oral long lasting
Brand erosion by drug formulation – Parenteral
Brand erosion by drug formulation – Other formulations
8. BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report
Brand erosion – methodology
Datamonitor prescription pharmaceutical definition and therapy area classification
[Inhaltsverzeichnis ausblenden]